Seo et al. [224] recently reported a chemo-immunotherapeutic strategy to target cervical cancer that employs a biodegradable chitosan-based hydrogel that can codeliver chemotherapeutic agent such as doxorubicin, cisplatin, or cyclophosphamide with an immunoadjuvant-granulocyte macrophage colony-stimulating factor (GMCSF). The gene discussed is CSF2; the disease is cervical cancer.